Publications
| Title | Abstract | Year Filter | PMID(sorted ascending) Filter |
|---|
| evaluation of species differences and the effects of storage duration and temperature on the anticollagenase efficacy of canine, feline, and equine serum on in vitro corneal degradation. | objective to evaluate species differences and effects of storage duration and temperature on the anticollagenase efficacy of canine, feline, and equine serum on in vitro corneal degradation. samples corneas and serum from dogs, cats, and horses. procedures clinically normal corneas from dogs, cats, and horses were harvested within 2 hours after euthanasia. serum samples from dogs, cats, and horses were collected and pooled by species. corneal specimens were incubated with collagenase derived fro ... | 2015 | 26512545 |
| letter regarding "dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (cordless [collagenase option for reduction of dupuytren long-term evaluation of safety study]): 5-year data". | 2015 | 26518325 | |
| collagenase clostridium histolyticum for the treatment of dupuytren's contracture: systematic review and economic evaluation. | dupuytren's disease is a slowly progressive condition of the hand, characterised by the formation of nodules in the palm that gradually develop into fibrotic cords. contracture of the cords produces deformities of the fingers. surgery is recommended for moderate and severe contractures, but complications and/or recurrences are frequent. collagenase clostridium histolyticum (cch) has been developed as a minimally invasive alternative to surgery for some patients. | 2015 | 26524616 |
| proposal to restrict the genus clostridium (prazmowski) to clostridium butyricum and related species. | the genus clostridium as presently constituted is phylogenetically and phenotypically incoherent. polyphasic taxonomic data indicate that the genus comprises a collection of very heterogeneous species. numerous phylogenetic studies, principally based on sequencing of the 16s rrna gene indicate that the genus clostridium should be restricted to clostridium cluster i as clostridium sensu stricto. despite these findings, authors continue to add new species to the genus clostridium that do not fall ... | 2015 | 26643615 |
| temporal evolution of mri characteristics in dogs with collagenase-induced intracerebral hemorrhage. | intracerebral hemorrhage (ich) is one of the most lethal types of stroke. neuroimaging techniques, particularly mri, have improved the diagnostic accuracy of ich. the mri characteristics of the evolving stages of ich in humans-but not those in dogs-have been described. in this study, we document the temporal mri characteristics in a canine model of collagenase-induced ich. specifically, ich was induced in 5 healthy beagles by injecting 500 u of bacterial collagenase from clostridium histolyticum ... | 2015 | 26678369 |
| clostridium histolyticum collagenase - is this a revolutionary medical treatment for peyronie's disease? | 2016 | 26683137 | |
| injectable collagenase clostridium histolyticum as a nonsurgical treatment for dupuytren's disease. | nonsurgical treatment of dupuytren's disease using collagenase clostridium histolyticum (cch). | 2016 | 26683416 |
| effects of different concentrations of injectable collagenase enzyme on capsular tissue around silicone implants: a preliminary experimental study for the development of a new treatment strategy. | in recent studies, collagen organization was blamed for the formation of capsular contracture which is still a challenging problem after silicone implant-based breast operations. in this study, effects of different concentrations of collagenase enzyme derived from clostridium histolyticum on the capsular tissue formation around the silicone implants were investigated. the injectable form of collagenase has a routine clinical use in the treatment of both dupuytren's and peyronie's diseases. | 2016 | 26715576 |
| salvage palmar fasciectomy after initial treatment with collagenase clostridium histolyticum. | 2016 | 26741888 | |
| reply: salvage palmar fasciectomy following initial treatment with collagenase clostridium histolyticum. | 2016 | 26741890 | |
| does collagenase injection disrupt or digest the dupuytren's cord: a magnetic resonance imaging study. | collagenase clostridium histolyticum has been extensively studied as a treatment modality for dupuytren's contracture. its mechanism of action has been documented. it is unknown whether injected collagenase weakens the dupuytren's cord sufficiently to cause failure during manipulation or if there is digestion and reduction in cord volume. we examined five patients with isolated contractures of the ring or middle metacarpalphalangeal (mp) joint using magnetic resonance imaging (mri) prior to inje ... | 2016 | 26768221 |
| collagenase treatment for dupuytren disease of the thumb and first web. | to evaluate the short-term effectiveness of collagenase clostridium histolyticum to treat thumb and first web contractures in dupuytren disease. | 2016 | 26803569 |
| dtb select: 2 | february 2016. | evidence for fibrates in secondary prevention of cvd ● impact of comorbidity on benefits of commonly prescribed drugs ● identifying patients at risk of inappropriate prescribing ● shared decision making to reduce antibiotic prescribing in primary care ● duration of bcg vaccine protection ● antivirals for bell's palsy revisited ● time to review blood pressure targets? ● adherence to computerised cbt in primary care ● collagenase clostridium histolyticum for dupuytren's contracture. | 2016 | 26825794 |
| acceleration of bone formation during fracture healing by poly(pro-hyp-gly)10 and basic fibroblast growth factor containing polycystic kidney disease and collagen-binding domains from clostridium histolyticum collagenase. | growth factor delivered in combination with animal-derived collagen materials has been used to accelerate bone fracture healing in human patients. however, the introduction of bovine proteins into humans carries the risk of zoonotic and immunologic complications. here, we developed a collagen-like polypeptide-based bone formation system consisting of poly(pro-hyp-gly)10 , which mimics the triple helical conformation of collagen, and basic fibroblast growth factor (bfgf) fused to the polycystic k ... | 2016 | 26833780 |
| effects of cocoa husk feeding on the composition of swine intestinal microbiota. | a two-diet/two-period change over experiment was performed to investigate the effects of cocoa husks, as a source of dietary fiber and polyphenols, on pig intestinal microbial composition. six pigs were fed a conventional cereal-based diet or a diet obtained by substitution of 7.5% of the conventional diet with cocoa husks for 3 weeks. experimental diets were isoproteic and isoenergetic. at the end of each 3 week testing period, samples of fresh feces were collected and analyzed for microbial co ... | 2016 | 26877143 |
| maternal weaning modulates emotional behavior and regulates the gut-brain axis. | evidence shows that nutritional and environmental stress stimuli during postnatal period influence brain development and interactions between gut and brain. in this study we show that in rats, prevention of weaning from maternal milk results in depressive-like behavior, which is accompanied by changes in the gut bacteria and host metabolism. depressive-like behavior was studied using the forced-swim test on postnatal day (pnd) 25 in rats either weaned on pnd 21, or left with their mother until p ... | 2016 | 26903212 |
| peyronie's disease: what's around the bend? | peyronie's disease (pd) is a fibrotic diathesis of the tunica albuginea that results in penile plaque formation and penile deformity, negatively affecting sexual and psychosocial function of both patients and their partners. in this review, we discuss the pd literature and pd treatment options, with special emphasis on potential future therapies. | 2017 | 26941488 |
| the modulatory effect of anthocyanins from purple sweet potato on human intestinal microbiota in vitro. | in order to investigate the modulatory effect of purple sweet potato anthocyanins (pspas) on human intestinal microbiota, pspas were prepared by column chromatography and their influence on intestinal microbiota was analyzed by monitoring the bacterial populations and analyzing short-chain fatty acid (scfa) concentrations at different time points. the numbers (log10 cell/ml) of bifidobacterium and lactobacillus/enterococcus spp., bacteroides-prevotella, clostridium histolyticum, and total bacter ... | 2016 | 26975278 |
| in vitro extraction and fermentation of polyphenols from grape seeds (vitis vinifera) by human intestinal microbiota. | the effects of several parameters on the extraction yield of total polyphenols from grape seeds by pressurized liquid extraction were investigated. the highest recovery of total polyphenols occurred at 80 °c within 5 min, and a single extraction allowed a recovery of more than 97% of total polyphenols. following the purification with macroporous resin, the effects of grape polyphenols (>94.8%) on human intestinal microbiota were monitored over 36 h incubation by fluorescence in situ hybridizatio ... | 2016 | 26980065 |
| results of smsna survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for peyronie's disease. | intralesional injection of collagenase clostridium histolyticum (cch) for peyronie's disease (pd) can result in serious adverse events such as hematoma formation and corporal rupture. | 2016 | 27045265 |
| collagenase clostridium histolyticum: emerging practice patterns and treatment advances. | this study aims to provide a comprehensive review of the role of collagenase clostridium histolyticum (cch). | 2016 | 27050718 |
| [effects of exogenous enzymes on the degradation of adhesive-dentin interfaces]. | to compare the effects of exogenous enzymes on the degradation of adhesive-dentin interface. | 2016 | 27117216 |
| patient satisfaction with collagenase. | to establish patient satisfaction after collagenase clostridium histolyticum (cch) injection. | 2016 | 27132016 |
| collagenase clostridium histolyticum in dupuytren's contracture: a systematic review. | in the last few years, the use of collagenase clostridium histolyticum for management of dupuytren's contracture has increased. the procedure of enzymatic fasciectomy has become popular because it is non-invasive, safe and fast to perform. | 2016 | 27151958 |
| corr(®) ors richard a. brand award: clinical trials of a new treatment method for adhesive capsulitis. | conservative and even surgical management of adhesive capsulitis often is prolonged and painful. management of adhesive capsulitis is lacking evidence-based controlled clinical trials. | 2016 | 27160746 |
| loss of stiffness in collagen-rich uterine fibroids after digestion with purified collagenase clostridium histolyticum. | uterine fibroids are a significant health problem. these common benign tumors occur in 70-80% of women before age 50 years and often cause bleeding and pain and can interfere considerably with daily life. current treatment options are limited. fibroids contain substantial amounts of altered and disordered collagens, which contribute to their bulk. targeting these collagens directly presents a novel treatment approach. | 2016 | 27177523 |
| peyronie's disease and injectable collagenase clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. | to report on an early adopter series of collagenase clostridium histolyticum (cch) for peyronie's disease (pd). postapproval studies of cch have been anticipated after recent food and drug administration authorization of its use for men with pd as definitive and durable nonsurgical interventions have been long desired. | 2016 | 27211926 |
| efficacy and safety of the collagenase of the bacterium clostridium histolyticum for the treatment of capsular contracture after silicone implants: ex-vivo study on human tissue. | the fibrotic capsule that surrounds silicone implants consists mainly of collagen. the fda-approved collagenase of the bacterium clostridium histolyticum provides a reasonable treatment option. safety and efficacy at the female breast site must be evaluated before clinical utilization. | 2016 | 27232716 |
| collagenase clostridium histolyticum in the management of peyronie's disease: a review of the evidence. | peyronie's disease (pd) is a connective tissue disorder resulting in the abnormal accumulation of scar or plaques in the tunica albuginea of the penis. the condition is characterized by two phases: an active, inflammatory phase, and a stable, chronic phase. collagenase clostridium histolyticum (cch) was isolated in the mid-1900s and postulated as a potential pharmacologic strategy for breaking down the abnormal connective tissue plaques of pd. prior to the introduction of cch, a wide variety of ... | 2016 | 27247629 |
| a non-aggressive, highly efficient, enzymatic method for dissociation of human brain-tumors and brain-tissues to viable single-cells. | conducting research on the molecular biology, immunology, and physiology of brain tumors (bts) and primary brain tissues requires the use of viably dissociated single cells. inadequate methods for tissue dissociation generate considerable loss in the quantity of single cells produced and in the produced cells' viability. improper dissociation may also demote the quality of data attained in functional and molecular assays due to the presence of large quantities cellular debris containing immune-a ... | 2016 | 27251756 |
| adipose tissue microbiota in humans: an open issue. | a specific 'adipose tissue' microbiota has been recently identified in mice and hypothesized in humans. the purpose of this study was to verify the presence of microbiota of human whole adipose tissue and isolated adipocytes by combining culture-dependent and independent methods. | 2016 | 27297798 |
| efficacy and safety of collagenase clostridium histolyticum injection for dupuytren's contracture in non-caucasian japanese patients (cord-j study): the first clinical trial in a non-caucasian population. | to assess the efficacy, safety and pharmacokinetics of 0.58 mg collagenase clostridium histolyticum injections for the treatment of dupuytren's contracture in japanese patients, we conducted a phase iii, multicentre, uncontrolled, open-label clinical study in patients with dupuytren's contracture. of the 77 patients, 66 achieved clinical success in the primary treated joint (86%; 95% confidence interval: 76% to 93%), confirming the efficacy of collagenase clostridium histolyticum injections. mor ... | 2016 | 27313184 |
| evaluation of skin anti-aging potential of citrus reticulata blanco peel. | the peel of citrus reticulata blanco is traditionally used as tonic, stomachic, astringent, and carminative. it is also useful in skin care. | 2017 | 27365982 |
| high-speed atomic force microscopy reveals strongly polarized movement of clostridial collagenase along collagen fibrils. | bacterial collagenases involved in donor infection are widely applied in many fields due to their high activity and specificity; however, little is known regarding the mechanisms by which bacterial collagenases degrade insoluble collagen in host tissues. using high-speed atomic force microscopy, we simultaneously visualized the hierarchical structure of collagen fibrils and the movement of a representative bacterial collagenase, clostridium histolyticum type i collagenase (colg), to determine th ... | 2016 | 27373458 |
| to remember: radiotherapy - a successful treatment for early dupuytren's disease. | dupuytren's disease (dd) is a common fibroproliferative condition of the hand which tends to cause progressive digital flexion contracture. therapeutic strategies to treat the disease include radiotherapy, injections of collagenase clostridium histolyticum, needle fasciotomy and extended surgical intervention dependent on involvement and duration of the disease. we have reviewed the literature with the aim to assess the conditions and effects of radiotherapy in dd. in early stages of the disease ... | 2016 | 27428598 |
| review of management options for patients with atypical peyronie's disease. | peyronie's disease (pd) is a wound-healing disorder of the tunica albuginea often associated with penile deformity. less commonly, patients with pd might display atypical presentations such as ventral curvature, hourglass deformity, significantly shortened penis, and/or multiplanar curvature. | 2017 | 27544298 |
| the impact of collagenase clostridium histolyticum introduction on dupuytren treatment patterns in the united states. | the u.s. food and drug administration approved the use of collagenase clostridium histolyticum (cch) in the united states in february 2010. this study addresses the impact of that approval on the number of dupuytren contracture (dc) encounters and treatment patterns in the united states. | 2016 | 27546441 |
| [comparative cost effectiveness of clostridium histolyticum collagenase (xiapex®) and partial fasciectomy for the treatment of dupuytren's contracture in austria]. | since dupuytren's contracture is a common disorder, the costs for its surgical treatment impose a considerable burden on the healthcare system. for the first time in the german-speaking area, this study aimed to provide a comparative cost-effectiveness analysis for partial fasciectomy vs. treatment with clostridium histolyticum collagenase (cch). | 2016 | 27547932 |
| cloning, purification and characterization of the collagenase cola expressed by bacillus cereus atcc 14579. | bacterial collagenases differ considerably in their structure and functions. the collagenases colh and colg from clostridium histolyticum and cola expressed by clostridium perfringens are well-characterized collagenases that cleave triple-helical collagen, which were therefore termed as ´true´ collagenases. cola from bacillus cereus (b. cereus) has been added to the collection of true collagenases. however, the molecular characteristics of b. cereus cola are less understood. in this study, we id ... | 2016 | 27588686 |
| toxic dermatitis secondary to treatment with collagenase clostridium histolyticum for dupuytren´s disease. | secondary effects and drug reactions relative to collagenase clostridium histolyticum treatment for dupuytren's contracture are frequent. in only a few cases these secondary effects are considered serious. the mechanism that produces these effects of production is not well understood. | 2016 | 27649672 |
| effectiveness and safety of collagenase clostridium histolyticum in dupuytren's disease : an observational study in belgium. | dupuytren's disease is a connective tissue disorder leading to contractures. it can be treated surgically or through injections of collagenase clostridium histolyticum (cch). patients with dupuytren's contracture (> 20°) and a palpable cord were included in this observational study, aiming to characterise the belgian patient population and to assess the effectiveness and safety of cch. overall, 108 patients (114 joints) received at least one injection of cch, and 104 patients completed the study ... | 2016 | 27682305 |
| matrix metalloproteinases as reagents for cell isolation. | cell isolation methods for therapeutic purposes have seen little advancement over the years. the original methods of stem cell and islet isolation using bacterial collagenases were developed in the early 1980s and are still used today. bacterial collagenases are subject to autodegradation, and isolates obtained with these enzymes may be contaminated with endotoxins, reducing cell viability and contributing to toxicity in downstream applications. here we describe a novel method for isolation of m ... | 2016 | 27702483 |
| collagenase clostridium histolyticum for the treatment of peyronie's disease: a 'real world' clinical perspective. | the introduction of collagenase clostridium histolyticum (cch) as a treatment option for peyronie's disease (pd), defined as the abnormal formation of collagen on the tunica albuginea of the penis, has provided patients with a promising new conservative therapy. studies have shown that cch improves curvature by an average of 17°, and although patient and sexual partner satisfaction is high, the improvement has arguable clinical implications. similarly, the efficacy and cost of cch contrasts stro ... | 2016 | 27770352 |
| the history of collagenase clostridium histolyticum. | after its u.s. fda approval in 2013, collagenase clostridium histolyticum (cch) has seen increasing use as a nonoperative treatment for peyronie's disease (pd). we review the history of cch and trials that led to its adoption. | 2015 | 27784601 |
| impact of number of cycles of collagenase clostridium histolyticum on outcomes in patients with peyronie's disease. | to analyze the impact of the number of cycles of collagenase clostridium histolyticum (cch) intralesional injection therapy on outcomes to further characterize cch therapy. | 2017 | 27816605 |
| association between infertility and sexual dysfunction in men and women. | the relation between infertility and sexual dysfunction can be reciprocal. causes of sexual dysfunction that affect fertility include erectile dysfunction, peyronie's disease (abnormal penile curvature), low libido, ejaculatory disorders in men, and genito-pelvic pain/penetration disorder (gpppd) and low sexual desire in women. | 2016 | 27872029 |
| in vitro studies to evaluate the wound healing properties of calendula officinalis extracts. | calendula officinalis (pot marigold) flower extracts have a long-lasting tradition in ethnopharmacology. currently, the european medicines agency (ema) has approved its lipophilic and aqueous alcoholic extracts as traditional medicinal products for the treatment of minor inflammation of the skin and as an aid in the healing of minor wounds. | 2017 | 27956358 |
| long-term effects of the collagenase of the bacterium clostridium histolyticum for the treatment of capsular fibrosis after silicone implants. | capsular contracture remains the most frequent long-term complication after augmentation mammoplasty with silicone implants. thereby, the main part of the fibrotic capsule is collagen. the collagenase of the bacterium clostridium histolyticum is approved for the treatment of fibrotic diseases and has been demonstrated to be effective for capsular fibrosis treatment in the short term. however, long-term effectiveness is currently unknown but mandatory for clinical utilization. | 2017 | 28008464 |
| intralesional collagenase clostridium histolyticum study provides real-world analysis. | 2016 | 28078227 | |
| trends in the treatment of dupuytren disease in the united states between 2007 and 2014. | background: dupuytren disease is a common fibroproliferative disorder. multiple procedural treatment options are available, with collagenase clostridium histolyticum (cch) injection being introduced in 2010. the purpose of this study was to investigate trends in the treatment of dupuytren disease in the united states between 2007 and 2014. methods: the pearldiver humana database was queried using international classification of diseases, ninth revision (icd-9) and current procedural terminology ... | 2017 | 28082837 |
| effect of freeze-dried allograft bone with human basic fibroblast growth factor containing a collagen-binding domain from clostridium histolyticum collagenase on bone formation after lumbar posterolateral fusion surgery in rats. | an experimental study. | 2017 | 28098745 |
| [treatment of dupuytren's disease with collagenase clostridium histolyticum]. | dupuytren's disease as a benign fibroproliferative disease leads to hyperplasia of the collagen fibers of the fascia of the palm, which can result in severe impairment of the functionality of the hand. | 2017 | 28138723 |
| pain associated with treatment of dupuytren contracture with collagenase clostridium histolyticum. | the primary objective of this study was to quantify the degree of pain associated with collagenase clostridium histolyticum (cch) injection and to determine whether it is related to other factors in the intervention. | 2017 | 28160905 |
| adverse effects of collagenase in the treatment of dupuytren disease: a systematic review. | collagenase clostridium histolyticum (cch) has proven to be both safe and effective in the treatment of dupuytren disease (dd). the medium-term outcomes are similar to those achieved with surgery, and most adverse effects are self-limiting and considered to be mild or moderate. | 2017 | 28181175 |
| survey of patient and partner satisfaction following collagenase clostridium histolyticum treatment for peyronie's disease. | intralesional injection of collagenase clostridium histolyticum (cch) is a minimally invasive, food and drug administration-approved, effective treatment for peyronie's disease (pd). to assess the satisfaction of patients and their female sexual partners (fsp) following cch therapy for pd, we conducted a retrospective review of the records of all patients treated with cch for pd between 04/2014 and 03/2016. collected variables included demographics, pre- and post-treatment sexual function, penil ... | 2017 | 28187522 |
| re: peyronie's disease and injectable collagenase clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. | 2017 | 28208540 | |
| re: results of smsna survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for peyronie's disease. | 2017 | 28217456 | |
| expanding the role of injectable collagenase clostridium histolyticum for the treatment of active phase peyronie's disease. | 2017 | 28217457 | |
| results of smsna survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for peyronie's disease. | 2017 | 28217458 | |
| complications and other concerns with intralesional injection therapy with collagenase clostridium histolyticum for peyronie's disease. | 2017 | 28217459 | |
| collagenase clostridium histolyticum intralesional injections for the treatment of peyronie's disease: a safety profile. | 2017 | 28217460 | |
| collagenase clostridium histolyticum in the treatment of peyronie's disease: patient selection and perspectives. | the safety and efficacy of the use of collagenase clostridium histolyticum (cch) for the treatment of peyronie's disease has been confirmed over the past several years. however, identification of the ideal patient population for use of this treatment is not well established. multiple studies have attempted to delineate various patient-specific factors that may predict response to treatment with cch, with the intent of enhancing patient selection. to date, these include baseline curvature severit ... | 2017 | 28280315 |
| multiple recurrences in aggressive forms of dupuytren's disease-can patients benefit from repeated selective fasciectomy? | in dupuytren's disease (dd), limited fasciectomy is the mainstay of surgical therapy in patients at risk of contractures and disease recurrences. new minimally invasive treatments such as injection of collagenase clostridium histolyticum have evolved as a common tool for the preliminary treatment of dupuytren's contractures. however, recurrences and their therapy remain controversial. in this study, we evaluate the benefit of repeated limited fasciectomy in patients with aggressive forms of the ... | 2017 | 28280681 |
| treatment of recurrent dupuytren contracture in joints previously effectively treated with collagenase clostridium histolyticum. | collagenase clostridium histolyticum (cch) is approved for the treatment of adults with dupuytren contracture with a palpable cord. this open-label, phase 4 study evaluated the safety and efficacy of cch for the retreatment of recurrent contractures in joints that were previously effectively treated with cch. | 2017 | 28341067 |
| clinical experience with penile traction therapy among men undergoing collagenase clostridium histolyticum for peyronie's disease. | to evaluate the outcomes in men undergoing collagenase clostridium histolyticum (cch) with concurrent penile traction therapy (ptt) for the treatment of peyronie's disease (pd). | 2017 | 28347795 |
| the use of residual collagenase for single digits with multiple-joint dupuytren contractures. | standard 0.58 mg (0.25 ml) collagenase clostridium histolyticum (cch) preparations result in unused cch that is often discarded. our purpose was to assess the results on dupuytren contractures affecting both the metacarpophalangeal (mcp) and proximal interphalangeal (pip) joints in the same digit utilizing an injection containing the maximum cch volume that can be withdrawn from a single vial. | 2017 | 28389081 |
| changes in the effects of peyronie's disease after treatment with collagenase clostridium histolyticum: male patients and their female partners. | collagenase clostridium histolyticum (cch) intralesional injection was efficacious for the management of peyronie's disease (pd) in the double-blinded, randomized, placebo-controlled investigation for maximal peyronie's reduction efficacy and safety studies i and ii (impress i and ii). little is known about the consequences of pd or treatment on the sexual partners of affected men. | 2017 | 28395998 |
| collagenase clostridium histolyticum in the treatment of urologic disease: current and future impact. | peyronie's disease (pd) is a connective tissue disorder resulting in the abnormal accumulation of type i to iii collagen, fibrin, and disorganized elastic fibers in the tunica albuginea of the penis. many medical and non-pharmacologic modalities have been used in the treatment of pd; however, these approaches have proved largely ineffective, with surgery being the only definitive treatment. intralesional injection of collagenase clostridium histolyticum (cch) has recently become the gold standar ... | 2017 | 28454897 |
| injectable collagenase versus percutaneous needle fasciotomy for dupuytren contracture in proximal interphalangeal joints: a randomized controlled trial. | collagenase clostridium histolyticum (cch) injection was introduced commercially as a treatment for dupuytren contracture following initial phase-3 investigations in 2009 with promising results. however, the efficacy of cch has not been prospectively investigated in a direct comparison to other active treatments of dupuytren contracture with more than 1-year follow-up, despite a wide and increasing clinical use. | 2017 | 28473158 |
| self-reported clinical meaningfulness early in the treatment course predicts objective outcomes in men undergoing collagenase clostridium histolyticum injections for peyronie disease. | to compare perceived meaningfulness early in the course of collagenase clostridium histolyticum (cch) with final outcomes to evaluate its use as a predictor of efficacy. | 2017 | 28483591 |
| safety profile of collagenase clostridium histolyticum stratified by degree of penile curvature in patients with peyronie disease. | to examine the safety of collagenase clostridium histolyticum (cch) in adult men with penile curvature deformity <30°. cch is indicated for treatment of peyronie disease in adult men with palpable plaque and a penile curvature deformity ≥30° at start of therapy; however, during treatment, patients may receive cch injections when penile curvature deformity is <30°. | 2017 | 28502596 |
| difference in success treating proximal interphalangeal and metacarpophalangeal joints with collagenase: results of 208 treatments. | dupuytren disease (dd) is a fibroproliferative disorder of the palmar fasciae causing extension deficit and impaired hand function. treatment with injection of collagenase clostridium histolyticum (cch) is a nonsurgical treatment method. the aim of this study was to evaluate the difference in efficiency and recurrence at 12-month follow-up when treating metacarpophalangeal (mp) and proximal interphalangeal (pip) joints with cch. none of the patients had received previous treatments of their cond ... | 2017 | 28507849 |
| in vitro approaches to assess the effects of açai (euterpe oleracea) digestion on polyphenol availability and the subsequent impact on the faecal microbiota. | a considerable proportion of dietary plant-polyphenols reach the colon intact; determining the effects of these compounds on colon-health is of interest. we hypothesise that both fibre and plant polyphenols present in açai (euterpe oleracea) provide prebiotic and anti-genotoxic benefits in the colon. we investigated this hypothesis using a simulated in vitro gastrointestinal digestion of açai pulp, and a subsequent ph-controlled, anaerobic, batch-culture fermentation model reflective of the dist ... | 2017 | 28551224 |
| factors associated with erectile dysfunction and the peyronie's disease questionnaire in patients with peyronie disease. | to elucidate patient characteristics that impact symptom-related bother and erectile function in patients with peyronie disease (pd). | 2017 | 28554517 |
| outcome of dupuytren contractures after collagenase clostridium histolyticum injection: a single-institution experience. | collagenase clostridium histolyticum (cch) injection is an alternative to surgery for patients with dupuytren disease (dd) of the metacarpophalangeal (mcp) and proximal interphalangeal (pip) joints. the success of surgical and nonsurgical treatment modalities for dd is reported to vary widely between 25% and 80% (j bone joint surg am. 1985;67:1439-1443; plast reconstr surg. 2007;120:44e-54e; j bone joint surg am. 2007;89:189-198; j hand surg am. 2011:36:936-942; j hand surg am. 1990;15:755-761; ... | 2017 | 28604542 |
| effect of cocoa's theobromine on intestinal microbiota of rats. | to establish the role of cocoa theobromine on gut microbiota composition and fermentation products after cocoa consumption in rats. | 2017 | 28605130 |
| safety and effectiveness of collagenase clostridium histolyticum in the treatment of peyronie's disease using a new modified shortened protocol. | to evaluate the efficacy and safety of collagenase clostridium histolyticum (cch; xiapex(®) , xiaflex(®) ) in the treatment of peyronie's disease (pd) using a new modified treatment protocol that aims at reducing the number of injections needed and reducing patient visits, thus reducing the duration and cost of treatment. | 2017 | 28612401 |
| complications following collagenase treatment for dupuytren contracture. | collagenase clostridium histolyticum (cch) injection and manipulation is a relatively new method for treating dupuytren contracture that is growing in popularity. although side effects such as swelling and ecchymosis are common, they are typically mild and self-limited. major complications are rare but have included flexor tendon rupture and complex regional pain syndrome. | 2017 | 28635316 |
| recent pathophysiological aspects of peyronie's disease: role of free radicals, rationale, and therapeutic implications for antioxidant treatment-literature review. | peyronie's disease (pd) is a chronic inflammation of tunica albuginea of the corpora cavernosa that causes an inelastic plaque resulting in penis deformation. although its etiology is not completely known, there is general consensus that pd is genetically transmitted and secondary to penile trauma. in recent years, numerous studies demonstrated the role played by oxidative stress in pd pathogenesis, and other studies have described successful use of antioxidants in pd treatment. oxidative stress ... | 2017 | 28744308 |
| basic fibroblast growth factor-anchored multilayered mesenchymal cell sheets accelerate periosteal bone formation. | cell-based regenerative therapy has the potential to repair bone injuries or large defects that are recalcitrant to conventional treatment methods, including drugs and surgery. here, we developed a multilayered cell-based bone formation system using cells coated with fibronectin-gelatin (fn-g) nanofilms. the multilayered mesenchymal cells (mlmcs) were formed after two days of culture and were shown to express higher levels of bmp-2 and vegf compared to monolayer cultures of mcs. the mlmcs were u ... | 2017 | 28761877 |
| re: clinical experience with penile traction therapy among men undergoing collagenase clostridium histolyticum for peyronie disease. | 2017 | 28817884 | |
| discovery of a potent inhibitor class with high selectivity toward clostridial collagenases. | secreted virulence factors like bacterial collagenases are conceptually attractive targets for fighting microbial infections. however, previous attempts to develop potent compounds against these metalloproteases failed to achieve selectivity against human matrix metalloproteinases (mmps). using a surface plasmon resonance-based screening complemented with enzyme inhibition assays, we discovered an n-aryl mercaptoacetamide-based inhibitor scaffold that showed sub-micromolar affinities toward coll ... | 2017 | 28820255 |
| collagenase treatment enhances proteomic coverage of low-abundance proteins in decellularized matrix bioscaffolds. | there is great interest in the application of advanced proteomic techniques to characterize decellularized tissues in order to develop a deeper understanding of the effects of the complex extracellular matrix (ecm) composition on the cellular response to these pro-regenerative bioscaffolds. however, the identification of proteins in ecm-derived bioscaffolds is hindered by the high abundance of collagen in the samples, which can interfere with the detection of lower-abundance constituents that ma ... | 2017 | 28829951 |
| efficacy and safety of collagenase clostridium histolyticum for dupuytren disease nodules: a randomized controlled trial. | to determine the safety and efficacy of collagenase clostridium histolyticum (cch) injection for the treatment of palmar dupuytren disease nodules. | 2017 | 28854973 |